Guide
Pesticide Registration: EPA Section 3 and EU 1107/2009 Side by Side
FIFRA Section 3 and EU Regulation 1107/2009 are the two reference frameworks for pesticide registration globally — most other markets pattern their data requirements on one of the two. The structures look different (EPA single-step; EU active-substance approval at EU level followed by zonal/member-state product authorisation) but the underlying data requirements largely overlap, with both relying on OECD test guidelines and OECD/OPPTS series. This guide compares the registration paths and the practical work to keep one dossier serving both.
Start free trial Free trial, no credit card, onboard in days, not months.
EPA Section 3 vs EU 1107/2009: structure compared
EPA Section 3 is a single registration covering the active and the end-use product, granted at federal level with state-level Section 24 follow-on. EU 1107/2009 is two-tier: active substances are approved at EU level (currently under Annex II), then plant protection products containing them are authorised by member states in three zones (Northern, Central, Southern) using the mutual recognition mechanism. EPA timelines run 3–4 years for a new active; EU 1107/2009 timelines run 3–5 years to active approval plus 12–24 months per zone for product authorisation.
Data requirements: OECD as the common substrate
Both EPA (40 CFR Part 158) and EU (Commission Regulation 283/2013 for active substances, 284/2013 for products) require OECD test guideline studies for tox, ecotox, residue, environmental fate, efficacy and physical-chemical properties. The major gaps: EPA still requires some OPPTS-specific endpoints; EU requires comparative assessment and candidates for substitution under Annex IV criteria; both have specific endocrine-disruptor screening expectations (EPA EDSP, EU 2018/605).
Active substance equivalence and source changes
EU 1107/2009 Article 38 and EPA Pesticide Registration Improvement Act (PRIA) both regulate changes to the active substance source. EU equivalence is determined under Commission Regulation 1141/2010 using a tiered comparison of 5-batch impurity profiles against the reference source. The recurring failure: a sourcing change that is a simple US notification triggers a full equivalence re-evaluation in the EU, with market access blocked during the review.
Endocrine disruption and the cut-off criteria
EU 1107/2009 imposes hazard-based cut-off criteria (Annex II point 3.6): substances that are CMR 1A/1B, PBT, vPvB or have endocrine-disrupting properties cannot be approved (with limited derogations). Commission Regulation 2018/605 defines the ED criteria; ECHA/EFSA guidance details the assessment. EPA does not have hazard-based cut-offs but runs the Endocrine Disruptor Screening Program (EDSP) and may impose use restrictions. Substances at risk of EU non-approval need an EU-specific replacement strategy.
A 120-day dual-dossier readiness path
Days 1–20: inventory every active × product × jurisdiction with current registration status and renewal date. Days 21–50: map OECD/OPPTS/EU endpoint matrix; flag missing or non-acceptable studies. Days 51–80: rebuild the 5-batch impurity profile for each active source; close equivalence gaps. Days 81–105: ED, CMR and PBT screening across the active portfolio; identify cut-off risk. Days 106–120: rehearse a zonal rapporteur completeness check and an EPA Pesticide Registration Improvement Act 30-day screening.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Industries this hits hardest
Frequently asked
Can I use the same studies for EPA and EU?
Yes for OECD guideline studies — both regulators accept them. The acceptance gap is usually format and contextual data (study director declaration, GLP statement, raw data availability), not the science.
How long does EU active substance approval take?
Currently 3–5 years from dossier submission to Commission decision, plus 12–24 months per zone for product authorisation. EPA Section 3 timelines for new actives run 3–4 years.
What is comparative assessment and substitution?
Under EU 1107/2009 Article 50, member states must conduct comparative assessment for products containing candidates for substitution and may refuse authorisation where safer alternatives exist. There is no direct EPA equivalent.
Does the new EU SUR (Sustainable Use Regulation) change registration?
The proposed Regulation on the Sustainable Use of Plant Protection Products (SUR) was withdrawn in 2024, but Directive 2009/128/EC remains in force. Watch for follow-on proposals during the 2026–2028 cycle.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
Spot something off? .